Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) FCF Margin (2020 - 2025)

Vivos Therapeutics has reported FCF Margin over the past 6 years, most recently at 138.44% for Q4 2025.

  • Quarterly FCF Margin fell 5556.0% to 138.44% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 100.92% through Dec 2025, down 1265.0% year-over-year, with the annual reading at 100.92% for FY2025, 1265.0% down from the prior year.
  • FCF Margin was 138.44% for Q4 2025 at Vivos Therapeutics, down from 60.7% in the prior quarter.
  • Over five years, FCF Margin peaked at 50.48% in Q4 2021 and troughed at 170.69% in Q1 2022.
  • The 5-year median for FCF Margin is 96.01% (2021), against an average of 101.7%.
  • Year-over-year, FCF Margin crashed -10688bps in 2021 and then skyrocketed 7764bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 50.48% in 2021, then plummeted by -60bps to 81.01% in 2022, then decreased by -3bps to 83.13% in 2023, then rose by 0bps to 82.88% in 2024, then plummeted by -67bps to 138.44% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's FCF Margin are 138.44% (Q4 2025), 60.7% (Q3 2025), and 111.91% (Q2 2025).